It’s essential to consider that some of these effects might also be mediated by the lack of LPL inhibition within the activated vasculature of the tumor, as a pan-lipase inhibitor also reduced FA uptake in tumor-associated ECs. The gene discussed is LPL; the disease is neoplasm.